On this page
Desonide
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Desonide | .5 mg/g | 204135 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 212473-001 | DESONIDE | OINTMENT | DESONIDE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | October 23, 2019 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260417). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Desonide ointment USP, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Desonide ointment USP, 0.05% should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide ointment USP, 0.05% should not be used with occlusive dressings.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Desonide ointment USP, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide ointment USP, 0.05% was approximately 6%. These adverse reactions were erythema, induration, pruritus, irritation, oiliness, and peripheral edema. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation. To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals, Inc. at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Description
openFDA Drug LabelingDESCRIPTION Desonide Ointment, 0.05% contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17- [(1-methylethylidene)bis(oxy)]-,(11β,16α-)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, desonide, the active ingredient in Desonide Ointment, 0.05%, is C 24 H 32 O 6 . It has the following structural formula: The molecular weight of desonide is 416.51. It is a white to off-white odorless powder which is soluble in methanol and practically insoluble in water. Each gram of Desonide Ointment, 0.05% contains 0.5 milligram of desonide in an ointment base consisting of mineral oil and white petrolatum. It is a smooth, uniform petrolatum-type ointment. Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied desonide ointment USP, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Desonide Ointment, 0.05% is supplied in 15 g tubes (NDC 72603-164-01) and 60 g tubes (NDC 72603-164-02). STORAGE Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing.
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: DESONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 62332-485-15 | 62332-485 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-485-15) / 15 g in 1 TUBE | October 24, 2019 |
| 62332-485-60 | 62332-485 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-485-60) / 60 g in 1 TUBE | October 24, 2019 |
| 46708-485-15 | 46708-485 | Alembic Pharmaceuticals Limited | 1 TUBE in 1 CARTON (46708-485-15) / 15 g in 1 TUBE | March 7, 2025 |
| 46708-485-60 | 46708-485 | Alembic Pharmaceuticals Limited | 1 TUBE in 1 CARTON (46708-485-60) / 60 g in 1 TUBE | March 7, 2025 |
| 72603-164-01 | 72603-164 | NORTHSTAR RX LLC | 1 TUBE in 1 CARTON (72603-164-01) / 15 g in 1 TUBE | September 7, 2023 |
| 72603-164-02 | 72603-164 | NORTHSTAR RX LLC | 1 TUBE in 1 CARTON (72603-164-02) / 60 g in 1 TUBE | September 7, 2023 |
| 45802-423-35 | 45802-423 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-423-35) / 15 g in 1 TUBE | August 22, 2006 |
| 45802-423-37 | 45802-423 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-423-37) / 60 g in 1 TUBE | September 18, 2006 |
| 51672-1281-1 | 51672-1281 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1281-1) / 15 g in 1 TUBE | August 3, 1994 |
| 51672-1281-3 | 51672-1281 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1281-3) / 60 g in 1 TUBE | August 3, 1994 |
| 62332-485 | 62332-485 | Alembic Pharmaceuticals Inc. | — | October 24, 2019 |
| 46708-485 | 46708-485 | Alembic Pharmaceuticals Limited | — | March 7, 2025 |
| 72603-164 | 72603-164 | NORTHSTAR RX LLC | — | September 7, 2023 |
| 45802-423 | 45802-423 | Padagis Israel Pharmaceuticals Ltd | — | August 22, 2006 |
| 51672-1281 | 51672-1281 | Sun Pharmaceutical Industries, Inc. | — | August 3, 1994 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.